Table 3. Effects of Atorvastatin and Rosuvastatin or Pitavastatin therapy on lipid levels, CEC and AREA between Non-CR and CR groups among patients without lipid-lowering treatment at baseline.
| Atorvastatin |
Rosuvastatin or Pitavastatin |
|||
|---|---|---|---|---|
| Non-CR (n = 4) | CR (n = 23) | Non-CR (n = 6) | CR (n = 24) | |
| men/women | 4/0 | 20/3 | 5/1 | 19/5 |
| dose of statin (mg/day) | 15.0 ± 3.5 | 13.9 ± 5.0 | R: 6.0 ± 2.9 (5) | R: 7.0 ± 5.3 (19) |
| P: 2 (1) | P: 2.0 ± 1.2 (5) | |||
| Non-statin drugs (number) | ||||
| Ezetimibe | 0 | 0 | 0 | 3 |
| n-3PUFA | 0 | 2 | 0 | 3 |
| Fibrate | 0 | 1 | 0 | 0 |
| BMI (kg/m2) | ||||
| baseline | 23.0 ± 2.0 | 24.0 ± 3.4 | 25.1 ± 4.9 | 24.8 ± 5.2 |
| follow-up | 23.2 ± 2.7 | 23.6 ± 2.9 | 25.6 ± 4.6 | 24.9 ± 5.3 |
| LDL-C (mg/dL) | ||||
| baseline | 153.5 ± 30.4 | 138.7 ± 28.4 | 133.2 ± 42.8 | 140.4 ± 35.2 |
| follow-up | 83.3 ± 11.6* | 77.0 ± 16.9*** | 93.2 ± 32.2* | 87.3 ± 19.6*** |
| Non-HDL-C (mg/dL) | ||||
| baseline | 178.8 ± 39.7 | 158.9 ± 31.4 | 150.7 ± 38.9 | 164.5 ± 37.5 |
| follow-up | 107.5 ± 17.6* | 97.0 ± 17.0*** | 121.2 ± 33.5 | 108.5 ± 21.6*** |
| ApoB (mg/dL) | ||||
| baseline | 117.3 ± 29.6 | 110.6 ± 18.9 | 101.7 ± 26.6 | 112.4 ± 26.2 |
| follow-up | 76.8 ± 13.4* | 71.0 ± 13.0*** | 87.5 ± 21.7 | 78.1 ± 15.3*** |
| MDA-LDL (U/L) | ||||
| baseline | 189.8 ± 77.2 | 178.9 ± 61.7 | 140.2 ± 49.5 | 169.7 ± 61.7 |
| follow-up | 119.5 ± 20.1 | 110.7 ± 34.9*** | 122.0 ± 32.1 | 115.2 ± 35.6*** |
| HDL-C (mg/dL) | ||||
| baseline | 50.3 ± 9.5 | 43.7 ± 9.6 | 47.5 ± 12.8 | 43.5 ± 10.0 |
| follow-up | 45.5 ± 7.0 | 44.1 ± 9.9 | 41.2 ± 5.8 | 48.0 ± 10.0* |
| ApoA-I (mg/dL) | ||||
| baseline | 133.3 ± 11.6 | 118.2 ± 18.4 | 123.2 ± 23.6 | 119.1 ± 19.8 |
| follow-up | 128.5 ± 7.7 | 123.4 ± 19.6 | 123.2 ± 22.2 | 128.6 ± 19.7* |
| CEC (relative value) | ||||
| baseline | 0.95 ± 0.14 | 0.88 ± 0.14 | 0.90 ± 0.09 | 0.86 ± 0.17 |
| follow-up | 0.89 ± 0.13 | 0.92 ± 0.16** | 0.93 ± 0.13 | 1.00 ± 0.19** |
| AREA (U/L) | ||||
| baseline | 605.2 ± 152.6 (3) | 749.3 ± 172.4 | 738.2 ± 163.5 (5) | 776.1 ± 155.7 (19) |
| follow-up | 667.9 ± 242.9 (3) | 729.5 ± 145.2 | 831.1 ± 417.6 (5) | 829.9 ± 200.3 (19) |
Data are expressed as mean ± SD or number. The number in parenthesis indicates actual number of analyzed cases. Seven samples at baseline were collected in fasting-state at the beginning of CR. The others were collected immediate before the emergency coronary angiography on admission. *p < 0.05, **p < 0.01, ***p < 0.0001 compared with the baseline by paired t-test. P = pitavastatin; R = rosuvastatin, other abbreviations as in text and Table 2.